LAVAL, QC, Aug. 6, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that it intends to spin off its leading eye health business into an independent publicly traded entity (“Bausch + Lomb – NewCo”) from the remainder of Bausch Health (“BHC”). The spinoff will establish two separate…
FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK)…
$500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS Association and I AM ALS to support an ALS biomarker study utilizing samples and data from the ongoing Phase 3 clinical trial of NurOwn® in ALS patients. The goal of…
NEW YORK — AstraZeneca PLC has made a preliminary approach to rival drug maker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health care deal on record. The UK company informally contacted Gilead last month to gauge its interest in a possible tie-up,…
Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was supposed to hand down a verdict on the drug this month, needs until September to make the decision. What happened? Novartis isn’t saying much. MORE……
Gilead will increase the number of doses of remdesivir it’s donating to the federal government in the next six weeks, STAT reported. The drugmaker had planned to donate 607,000 vials of remdesivir — the drug that received FDA emergency approval for use in treating COVID-19 patients after it was shown to shorten recovery time in patients with the virus…
Compass Pathways has raised $80 million to prepare its psilocybin therapy for phase 3 development. The London-based biotech is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression. Psilocybin was studied in the 1960s, but research ground to a halt over the following decades. Teams at academic centers including the…
The COVID-19 pandemic and the ensuing societal countermeasures are upending operations in many sectors—and biopharma isn’t immune. The current lockdown is not only hurting clinical trial enrollment but also delaying regulatory timelines for drugs nearing a decision. And with tried-and-true, in-person marketing techniques no longer allowed, new launches may also feel the pain—or hold off altogether. Consider Bristol…
Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2. Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer,…
A Biogen employee who has contracted Covid-19 in Massachusetts fled to Beijing alongside her family. And now she faces criminal charges for lying about her condition on the way back. The company confirmed to Endpoints News that the woman, identified by Chinese officials as Ms. Li, works for the company but said she didn’t attend the strategy…
